Creso Pharma Limited Stock Price To Book
| COPHFDelisted Stock | USD 0.12 0.00 0.00% |
Creso Pharma Limited fundamentals help investors to digest information that contributes to Creso Pharma's financial success or failures. It also enables traders to predict the movement of Creso Pink Sheet. The fundamental analysis module provides a way to measure Creso Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Creso Pharma pink sheet.
Creso |
Creso Pharma Limited Company Price To Book Analysis
Creso Pharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Creso Pharma Price To Book | 0.36 X |
Most of Creso Pharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Creso Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Creso Pharma Limited has a Price To Book of 0.3561 times. This is 98.61% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to book for all United States stocks is 96.26% higher than that of the company.
Creso Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Creso Pharma's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Creso Pharma could also be used in its relative valuation, which is a method of valuing Creso Pharma by comparing valuation metrics of similar companies.Creso Pharma is currently under evaluation in price to book category among its peers.
Creso Fundamentals
| Return On Equity | -0.67 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.41) % | |||
| Operating Margin | (2.39) % | |||
| Current Valuation | 24.06 M | |||
| Shares Outstanding | 2 B | |||
| Shares Owned By Insiders | 26.99 % | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 4.68 X | |||
| Revenue | 6.22 M | |||
| Gross Profit | (400.39 K) | |||
| EBITDA | (28.06 M) | |||
| Net Income | (30.03 M) | |||
| Cash And Equivalents | 3.14 M | |||
| Total Debt | 3.26 M | |||
| Debt To Equity | 0.24 % | |||
| Current Ratio | 2.68 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (22.38 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 19 | |||
| Beta | 2.61 | |||
| Market Capitalization | 49.92 M | |||
| Total Asset | 29.31 M | |||
| Z Score | 9.0 | |||
| Net Asset | 29.31 M |
About Creso Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Creso Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Creso Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Creso Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Creso Pink Sheet
If you are still planning to invest in Creso Pharma Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Creso Pharma's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |